Introduction {#s1}
============

Compelling evidence demonstrates that both obesity and other related traits have a significant genetic component [@pone.0100489-deOliveiraCM1], and that these phenotypes result from an interaction between the genetic background and environmental factors [@pone.0100489-Speakman1]. The beta2-adrenergic receptor gene (ADRB2), as a lipolytic receptor in human fat cells, is associated with lipid mobilization. The most common single nucleotide polymorphism (SNP) occurs at codon 16 (Arg16Gly; rs1042713) and codon 27 (Gln27Glu; rs1042714). By altering the amino acid sequence in the extracellular N-terminus of the ADRB2, the rs1042713 and rs1042714 allele mutations are believed to alter ADRB2 function [@pone.0100489-Reihsaus1].

A number of polymorphisms have been well-studied in ADRB2 and obesity. However, individual reports regarding ADRB2 polymorphisms with obesity have produced inconsistent results. For example, a previous study including 4,193 Japanese subjects indicated that rs1042713 was not a major contributing factor for obesity in Japanese men [@pone.0100489-Pereira1]. However, another study [@pone.0100489-Lee1] showed that beta2-adrenoceptor polymorphisms may contribute to the development of obesity through gene-environmental interactions. Large et al. [@pone.0100489-Large1] found that in Swedish women obesity was associated with rs1042714, but not with rs1042713. The conflicting results of such studies may be a result of statistical underpower from sample sizes that were too small to detect any relationship between ARDB2 and risk of obesity. Therefore, we performed a meta-analysis of all published case-control or cohort studies to clarify the association of ADRB2 polymorphism with obesity susceptibility.

Materials and Methods {#s2}
=====================

Publication search and inclusion criteria and exclusion criteria {#s2a}
----------------------------------------------------------------

The first report of significance of ADRB2 was published in 1954 [@pone.0100489-Zamboni1], therefore we selected the starting date of 1950 (and last search date of April 19, 2014) for the article search in Pubmed, Embase, and the China National Knowledge Infrastructure. The search terms used were: "Beta2-adrenergic receptor", "β2-adrenergic receptor", "ADRB2", "polymorphism," and "obesity". No language restrictions were imposed. For articles with overlapping data, we selected the publication with the most extensive data available.

To be included in the meta-analysis, the identified articles had to meet all the following criteria: a) evaluation of Gln27Glu (rs1042714) or Arg16Gly (rs1042713) polymorphism and obesity, b) inclusion of quantitative information on the estimated risk of ADRB2 Gln27Glu (rs1042714) and/or Arg16Gly (rs1042713) polymorphism for obesity, and c) inclusion of complete information about all genotype frequencies, d) used a case control or cohort or cross sectional design, randomization or blinding is not necessary; The exclusion criteria were as follows: a) papers not related to ARDB2 polymorphism and obesity research, b) review articles, commentaries, or unpublished reports, c) papers without usable data, and d) duplicate publications.

Data extraction and quality assessment {#s2b}
--------------------------------------

We followed the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines for reporting meta-analysis of observational studies [@pone.0100489-Stroup1]. The following items from each individual study were extracted: the name of the first author, year of publication, number of patients, gender, country, ethnicity, body mass index (BMI) cut point, sample size of obesity and control groups. The first stage was a review of titles and/or abstracts for all identified citations, followed by a second review stage of full text publications. Two reviewers (HXZ and LPY) independently assessed the eligibility of studies, and the third investigator (JW) arbitrated any disagreements by discussion and consensus. If allele frequencies were not provided, they were calculated from the corresponding genotype distributions. For information not available in the published paper, relevant data was obtained by contacting the corresponding authors. Two reviewers (HXZ and LPY) also assessed independently rated the methodological quality of every included study by the "Newcastle-Ottawa Quality Assessment Scale" (NOS)[@pone.0100489-Wells1]. This scale contains nine items (1 point for each) in three parts: selection (four items), comparability (two items) and exposure (three items).

Some authors provided data only on subjects of one gender, some authors gave information on subjects of each gender, while others failed to report gender at all (gender not identified). The latter studies were included only in the group of both genders combined. Then we calculated the Hardy-Weinberg equilibrium for every study, both in the main group and in the gender-based subgroups. Eventually, 18 publications were enrolled in the main analyses, including 15 case control studies, one random study, one cross sectional study and one cohort study. Using these genotype comparisons, we pooled together the populations of both genders from all studies, and performed gender-based subgroup analyses that included all suitable studies. Nine publications were included for the ADRB2 Arg16Gly (rs1042713) gender-based groups and 17 publications were enrolled for the Gln27Glu (rs1042714) gender-based groups.

Statistical analysis {#s2c}
--------------------

Summary statistics were estimated in Review Manager 5.1 software (RevMan 5.1, Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2011). The association between the rs1042714 gene polymorphism and obesity was compared by the odds ratio (OR) with its 95% confidence intervals (CIs). The statistical significance of the summary OR was determined with the Z-test. Five comparisons were performed between the two groups: frequency of allele (Gln vs. Glu), heterozygote comparison (Gln/Glu vs. Gln/Gln), homozygote comparison (Glu/Glu vs. Gln/Gln), dominant model (Gln/Glu + Glu/Glu vs. Gln/Gln) and recessive model (Glu/Glu vs. Gln/Gln + Gln/Glu) of ADRB2 Gln27Glu. For the rs1042713 (Arg16Gly) polymorphism, we used the same strategy, by replacing Glu27 with Arg16. Five comparisons were performed between two groups: frequency of allele (Arg vs. Gly), heterozygote (Arg/Gly vs. Arg/Arg), homozygote (Gly/Gly vs. Arg/Arg), dominant model (Arg/Gly + Gly/Gly vs. Arg/Arg) and recessive model (Gly/Gly vs. Arg/Arg + Arg/Gly) of ADRB2 Arg16Gly.

In consideration of the possibility of heterogeneity among the studies, a statistical test for heterogeneity was examined by the Chi-square-based Q-test, and the significance was fixed at the level P\<0.05. The inconsistency index *I* ^2^ was also calculated to evaluate the variation caused by the heterogeneity. A high value of *I* ^2^ indicated a higher probability of the existence of heterogeneity. A random-effects model (DerSimonian and Laird method) was used if substantial heterogeneity was detected (Q-statistic: P\<0.10; *I* ^2^\>50%). Otherwise, a fixed-effect model was applied in the absence of between-study heterogeneity (Q-statistic: P\>0.10; *I* ^2^\< 50%). The significance of the pooled OR was determined by the Z-test, and the significance was set at P\<0.05. Fisher\'s exact test was used to assess the Hardy-Weinberg equilibrium, and the significance was set at P\<0.05. Potential publication bias was estimated using a funnel plot. Egger\'s linear regression test was used to evaluate the funnel plot asymmetry on the natural logarithmic scale of the OR (P\<0.05 was statistically significant). We also further investigated the rs1042714 and rs1042713 gene polymorphism with obesity stratifying the population based on gender.

Results {#s3}
=======

Study characteristics {#s3a}
---------------------

According to the search strategy, 34 published articles were identified for potential inclusion with full text obtained for ADRB2 polymorphism and obesity. Three articles were excluded because two papers were correspondences [@pone.0100489-Sakane1], [@pone.0100489-HMatsuoka1] and another because it was a review [@pone.0100489-Liu1]. 12 studies were excluded because groups were not divided by BMI [@pone.0100489-Large1], [@pone.0100489-Ruiz1], [@pone.0100489-Hayakawa1], [@pone.0100489-Phares1], [@pone.0100489-Carlsson1], [@pone.0100489-Terra1], [@pone.0100489-Ellsworth1], [@pone.0100489-Ellsworth2], [@pone.0100489-Ukkola1], [@pone.0100489-Rauhio1], [@pone.0100489-NakaI1], [@pone.0100489-Gjesing1] and one paper was excluded due to the fact that data correlating ADRB2 with obesity were not available[@pone.0100489-Mattevi1]. Thus, 18 studies [@pone.0100489-Pereira1], [@pone.0100489-Large1], [@pone.0100489-Chou1], [@pone.0100489-Masuo1], [@pone.0100489-GonzalezSanchez1], [@pone.0100489-Iwamoto1], [@pone.0100489-MalczewskaMalec1], [@pone.0100489-Kim1], [@pone.0100489-Oberkofler1], [@pone.0100489-Meirhaeghe1], [@pone.0100489-IshiyamaShigemoto1], [@pone.0100489-Echwald1], [@pone.0100489-Hellstrom1], [@pone.0100489-Kortner1], [@pone.0100489-Mori1], [@pone.0100489-Martinez1], [@pone.0100489-Angeli1], [@pone.0100489-Wu1] met our inclusion criteria. Of these, 17 papers involving 9,995 subjects genotyped at rs1042714 (all except Angeli et al. [@pone.0100489-Angeli1]) and 10 studies [@pone.0100489-Pereira1], [@pone.0100489-Large1], [@pone.0100489-Chou1], [@pone.0100489-Masuo1], [@pone.0100489-Iwamoto1], [@pone.0100489-Kim1], [@pone.0100489-Oberkofler1], [@pone.0100489-IshiyamaShigemoto1], [@pone.0100489-Angeli1], [@pone.0100489-Wu1] including 7,322 subjects genotyped at rs1042713 were included. A flow chart of study selection is shown in [Fig. 1](#pone-0100489-g001){ref-type="fig"}. The distribution of genotypes in all included studies was consistent with the Hardy-Weinberg equilibrium. The key characteristics of these articles are summarized in [Table 1](#pone-0100489-t001){ref-type="table"}.

![Flow diagram of articles selection process for ADRB2 gene polymorphism and obesity risk.](pone.0100489.g001){#pone-0100489-g001}
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###### Characteristics of studies ofADRB2 polymorphisms between obese people and controls included in the meta-analysis.

![](pone.0100489.t001){#pone-0100489-t001-1}

  Article (rs1042714)                                            Year   total number of patients        Study type         Gender(males/females)   Country           Ethnicity            BMI cut point    Sample size  
  ------------------------------------------------------------- ------ -------------------------- ----------------------- ----------------------- --------- --------------------------- ----------------- ------------- ---------------
  Large et al [@pone.0100489-Large1]                             1997             140                  Case control                0/140           Sweden             Swedish                  27              82             58
  Echwald et al [@pone.0100489-Echwald1]                         1998             205                  Case control                205/0           Denmark            Danish                   27              78             127
  Hellstrom et al [@pone.0100489-Hellstrom1]                     1999             247                  Case control               138/109          Sweden             Swedish                  27              125            122
  Kortner et al [@pone.0100489-Kortner1]                         1999             442                  Case control               184/258          Germany            German                   40              243            199
  Mori et al [@pone.0100489-Mori1]                               1999             278                  Case control                278/0            Japan            Japanese                 26.4             61             217
  Ishiyama-Shigemoto et al [@pone.0100489-IshiyamaShigemoto1]    1999             508                  Case control               344/164           Japan            Japanese                  27              108            400
  Oberkofler[@pone.0100489-Oberkofler1]                          2000             399                  Case control                0/399           Austria           Austrian                  27              183            216
  Meirhaeghe et al [@pone.0100489-Meirhaeghe1]                   2000             836                  Random study               419/417          France             French                   30              119            717
  Iwamoto et al [@pone.0100489-Iwamoto1]                         2001             251                  Case control                251/0            Japan            Japanese                  25              151            100
  Kim et al [@pone.0100489-Kim1]                                 2002             195                  Cohort study               101/94            Korea             Korean                   27              108            87
  Martinez et al [@pone.0100489-Martinez1]                       2003             313                  Case control               61/252            Spain             Spanish                  30              159            154
  González Sánchez et al [@pone.0100489-GonzalezSanchez1]        2003             666              cross sectional study          319/347           Spain             Spanish                  30              186            477
  Malczewska-Malec\[29                                           2003              38                  Case control                38/0            Poland             Polish                   30              22             16
  Masuo et al [@pone.0100489-Masuo1]                             2006             329                  Case control                329/0            Japan            Japanese                  25              123            206
  Wu et al [@pone.0100489-Wu1]                                   2009             396                  Case control               223/173           China             Chinese                  25              126            270
  Pereira et al [@pone.0100489-Pereira1]                         2011             4193                 Case control              2282/1911          Japan            Japanese                  25             1200           2993
  Chou et al [@pone.0100489-Chou1]                               2012             559                  Case control               275/284          Taiwan              Mixed             95th percentile       278            281
  Article (rs1042713)                                            Year   total number of patients        Study type         Gender(males/females)   Country           Ethnicity            BMI cut point    Sample size  
                                                                                                                                                                                                             Obesity     Normal weight
  Large et al [@pone.0100489-Large1]                             1997             140                  Case control                0/140           Sweden             Swedish                  27              82             58
  Ishiyama-Shigemoto et al [@pone.0100489-IshiyamaShigemoto1]    1999             508                  Case control               344/164           Japan            Japanese                  27              108            400
  Oberkofler et al [@pone.0100489-Oberkofler1]                   2000             399                  Case control                0/399           Austria           Austrian                  27              183            216
  Iwamoto et al [@pone.0100489-Iwamoto1]                         2001             251                  Case control                251/0            Japan            Japanese                  25              151            100
  Kim et al [@pone.0100489-Kim1]                                 2002             195                  Cohort study               101/94            Korea             Korean                   27              108            87
  Masuo et al [@pone.0100489-Masuo1]                             2006             329                  Case control                329/0            Japan            Japanese                  25              123            206
  Wu et al [@pone.0100489-Wu1]                                   2009             396                  Case control               223/173           China             Chinese                  25              126            270
  Pereira et al [@pone.0100489-Pereira1]                         2011             4193                 Case control              2282/1911          Japan            Japanese                  25             1200           2993
  Angeli et al [@pone.0100489-Angeli1]                           2011             361                  Case control        Gender not identified   Brazil    African-derived Brazilian         25              140            221
  Chou et al [@pone.0100489-Chou1]                               2012             559                  Case control               275/284          Taiwan              Mixed             95th percentile       278            281

Abbreviations: BMI, body mass index; ADRB2, Beta 2-adrenergic receptor gene; Gln27Glu (rs1042714), at codon 27; Arg16Gly (rs1042713), at codon 16.

### Methodological quality of 18 studies including our meta-analysis {#s3a1}

Overall, the methodological quality of the 18 studies was modest. In general, the mixture studies including 15 case control studies, one random study, one cross sectional study and one cohort study. The studies failed to protect against selection bias: the definition of obesity used for the study is not uniform. None of the studies used secure methods for ascertainment of exposure. The majority of the studies provided evidence on the reliability of methods for outcome assessment; however, only several studies explicitly stated that outcome assessment was blind to exposure status. Finally, only two publications [@pone.0100489-Pereira1], [@pone.0100489-Angeli1] including in our meta-analysis clearly declared that no conflict with interest, others did not mention that ([TableS1](#pone.0100489.s001){ref-type="supplementary-material"}). Methodological quality of 18 articles enrolled in our study presented in [Table 2](#pone-0100489-t002){ref-type="table"}.

10.1371/journal.pone.0100489.t002

###### Methodological quality of 18 articles enrolled in our study by the "Newcastle-Ottawa Quality Assessment Scale".

![](pone.0100489.t002){#pone-0100489-t002-2}

  included studies                                                                             Selection   Comparability   Exposure   Total Quality score                           
  ------------------------------------------------------------------------------------------- ----------- --------------- ---------- --------------------- ---- ---- ---- ---- ---- ---
  Large 1997                                                                                      \*            \*            \*              \*            \*   \*        \*   \*   8
  Echwald 1998                                                                                    \*            \*            \*              \*                           \*   \*   6
  Hellstrom 1999                                                                                  \*            \*            \*              \*            \*   \*        \*   \*   8
  Ishiyama-Shigemoto 1999                                                                         \*            \*            \*              \*                 \*        \*   \*   7
  Kortner 1999                                                                                    \*            \*            \*              \*                           \*   \*   6
  Mori 1999                                                                                       \*            \*            \*              \*                           \*   \*   6
  Meirhaeghe 2000                                                                                 \*            \*            \*              \*            \*   \*   \*   \*   \*   9
  Oberkofler 2000                                                                                 \*            \*            \*              \*                 \*        \*   \*   7
  Iwamoto 2001                                                                                    \*            \*            \*              \*            \*             \*   \*   7
  Kim 2002 Subjects exclude sex ration,age,blood pressure,serum LDL,HDL,serum triglycerides       \*            \*            \*              \*            \*   \*        \*   \*   8
  González Sánchez 2003                                                                           \*            \*            \*              \*            \*             \*   \*   7
  Malczewska-Malec 2003                                                                           \*            \*            \*              \*                 \*        \*   \*   7
  Martinez 2003                                                                                   \*            \*            \*              \*                           \*   \*   6
  Masuo 2006                                                                                      \*            \*            \*              \*            \*   \*        \*   \*   8
  Wu 2009                                                                                         \*            \*            \*              \*            \*             \*   \*   7
  Angeli 2011                                                                                     \*            \*            \*              \*            \*   \*   \*   \*   \*   9
  Pereira 2011                                                                                    \*            \*            \*              \*            \*   \*   \*   \*   \*   9
  Chou 2012                                                                                       \*            \*            \*              \*            \*   \*        \*   \*   8

Meta-analysis {#s3b}
-------------

In the meta-analysis, 17 studies involved the rs1042714 (Gln27Glu) gene polymorphism, and 10 studies met our criteria for the rs1042713 (Arg16Gly) polymorphism. The frequency of occurrence of ADRB2 Gln27Glu/Arg16Gly allele in the population and their distribution among various populations are presented in [table 3](#pone-0100489-t003){ref-type="table"}. A random-effects model was used if substantial heterogeneity was detected (Q-statistic: P\<0.10; *I* ^2^\>50%) or a fixed-effect model was applied in the absence of between-study heterogeneity (Q-statistic: P\>0.10; *I* ^2^\<50%). Meta-analysis of rs1042714 (Gln27Glu) and rs1042713 (Arg16Gly) polymorphism on risk of obesity are shown in [Table 4](#pone-0100489-t004){ref-type="table"} and [Table 5](#pone-0100489-t005){ref-type="table"}, respectively. As shown in [Table 4](#pone-0100489-t004){ref-type="table"} and [Fig. 2](#pone-0100489-g002){ref-type="fig"}, in the analysis of the rs1042714 (Gln27Glu) gene polymorphism, the heterozygote model in our current study exhibited a significant difference (Gln/Glu vs. Gln/Gln: OR: 1.16, 95% CI: 1.04--1.30, *I* ^2^ = 49%, P = 0.009), indicating that risk of developing obesity with Gln/Glu heterozygotes was 1.16 times higher than those with Gln/Gln homozygotes. Additionally, the dominant model also exhibited a significant difference (Gln/Glu + Glu/Glu vs. Gln/Gln: OR: 1.2, 95% CI: 1.00--1.44, *I* ^2^ = 55%, P = 0.04), suggesting that risk of developing obesity with the Gln/Glu plus Glu/Glu genotype was 1.2 times higher than with the Gln/Gln homozygotes ([Table 4](#pone-0100489-t004){ref-type="table"} and [Fig. 3](#pone-0100489-g003){ref-type="fig"}). On the other hand, no significant correlation between obesity and Gln27Glu genetic variant in ADRB2 was found in the other three comparisons ([Table 4](#pone-0100489-t004){ref-type="table"}). Our meta-analysis also showed that in all genetic models there was no significant association between Arg16Gly genetic variant in ADRB2 and the risk of obesity ([Table 5](#pone-0100489-t005){ref-type="table"}).

![Association between rs1042714 (Gln27Glu) gene polymorphism and obesity risk under heterozygote model.\
(Gln/Glu vs. Gln/Gln: OR: 1.16, 95% CI: 1.04--1.30, *I* ^2^ = 49%, P = 0.009).](pone.0100489.g002){#pone-0100489-g002}

![Association between rs1042714 (Gln27Glu) gene polymorphism and obesity risk under dominant model.\
(Gln/Glu + Glu/Glu vs. Gln/Gln: OR: 1.2, 95% CI: 1.00--1.44, *I* ^2^ = 55%, P = 0.04).](pone.0100489.g003){#pone-0100489-g003}

10.1371/journal.pone.0100489.t003

###### Distributions of ADRB2 Gln27/Glu and Arg16/Gly genotypes of eligible studies included in the meta-analysis.
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  year                        Article (Gln27/Glu)                        cases    controls                                                                                       
  ------ ------------------------------------------------------------- --------- ---------- --------- --------------- ------------ --------- --------- --------- --------------- ------------
  1997                Large et al [@pone.0100489-Large1]                  24         38        20           86             78         25        31         2           81             35
  1998              Echwald et al [@pone.0100489-Echwald1]                25         42        11           92             64         47        59        21           153           101
  1999            Hellstrom et al [@pone.0100489-Hellstrom1]              46         58        21           150           100         43        59        20           145            99
  1999              Kortner et al [@pone.0100489-Kortner1]                77        130        36           284           202         74        85        40           233           165
  1999                 Mori et al [@pone.0100489-Mori1]                   48         13         0           109            13         201       15         1           417            17
  1999    Ishiyama-Shigemoto et al [@pone.0100489-IshiyamaShigemoto1]     81         24         3           186            30         346       52         2           744            56
  2000               Oberkofler[@pone.0100489-Oberkofler1]                77         87        19           241           125         86        96        34           268           164
  2000           Meirhaeghe et al [@pone.0100489-Meirhaeghe1]             53         51        15           157            81         224       375       118          823           611
  2001              Iwamoto et al [@pone.0100489-Iwamoto1]                118        33         0           269            33         84        16         0           184            16
  2002                  Kim et al [@pone.0100489-Kim1]                    34         11         0           79             11         34         9         0           77             9
  2003             Martinez et al [@pone.0100489-Martinez1]               57        102         0           216           102         62        92         0           216            92
  2003      González Sánchez et al [@pone.0100489-GonzalezSanchez1]       68         88        30           224           148         191       224       62           606           348
  2003          lczewska-Malec[@pone.0100489-MalczewskaMalec1]            13         6          3           32             12          8         6         2           22             10
  2006                Masuo et al [@pone.0100489-Masuo1]                  104        19         0           227            19         192       14         0           398            14
  2009                   Wu et al [@pone.0100489-Wu1]                     106        20         0           232            20         226       43         1           495            45
  2011              Pereira et al [@pone.0100489-Pereira1]               1025       166         9          2216           184        2616       361       16          5593           393
  2012                 Chou et al [@pone.0100489-Chou1]                   229        42         3           500            48         229       44         3           502            50
                              Article (Arg16/Gly)                        cases    Controls                                                                                       
                                                                        Arg/Arg   Arg/Gly    Gly/Gly   Arg 16 allele   Gly allele   Arg/Arg   Arg/Gly   Gly/Gly   Arg 16 allele   Gly allele
  1997                Large et al [@pone.0100489-Large1]                  14         31        37           59            105         13        14        31           40             76
  1999    shiyama-Shigemoto et al [@pone.0100489-IshiyamaShigemoto1]      11         24        16           46             56         70        154       69           294           292
  2000              Oberkofler [@pone.0100489-Oberkofler1]                37         83        63           157           209         36        102       78           174           258
  2001              Iwamoto et al [@pone.0100489-Iwamoto1]                37         75        39           149           153         26        48        26           100           100
  2002                  Kim et al [@pone.0100489-Kim1]                    18         23         5           59             33         17        22         4           56             30
  2006                Masuo et al [@pone.0100489-Masuo1]                  27         62        34           116           130         77        88        41           242           170
  2009                   Wu et al [@pone.0100489-Wu1]                     36         72        18           144           108         82        138       50           302           238
  2011              Pereira et al [@pone.0100489-Pereira1]                156       312        174          624           660         396       789       455         1581           1699
  2011               Angeli et al [@pone.0100489-Angeli1]                 26         77        37           129           151         45        107       69           197           245
  2012                 Chou et al [@pone.0100489-Chou1]                   47         62        28           156           118         46        60        28           152           116

ADRB2, Beta 2-adrenergic receptor gene; Gln27Glu (rs1042714), at codon 27; Arg16Gly (rs1042713), at codon 16.

10.1371/journal.pone.0100489.t004

###### Meta-analysis of rs1042714 (Gln27Glu) polymorphism on risk of obesity.
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  Comparisons rs1042714 (Gln27Glu) polymorphism and obesity (17studies)     OR      95%CI     *I^2^*(%)    *P*
  ----------------------------------------------------------------------- ------ ----------- ----------- -------
  Allele frequency comparison (Gln vs. Glu)                                0.86   0.74,1.01      61       0.06
  Gender-based subgroup analysis with men                                  0.86   0.68,1.10      63       0.23
  Gender-based subgroup analysis with women                                0.86   0.67,1.09      67       0.21
  Heterozygote comparison (Gln/Glu vs. Gln/Gln)                            1.16   1.04,1.30      49       0.009
  Gender-based subgroup analysis with men                                  1.22   0.90,1.65      62       0.21
  Gender-based subgroup analysis with women                                1.13   0.95,1.34       0       0.16
  Homozygote comparison (Glu/Glu vs. Gln/Gln)                              1.01   0.81,1.27      44       0.92
  Gender-based subgroup analysis with men                                  0.9    0.63,1.29      25       0.58
  Gender-based subgroup analysis with women                                1.34   0.73,2.45      64       0.35
  Dominant model (Gln/Glu + Glu/Glu vs. Gln/Gln)                           1.2    1.00,1.44      55       0.04
  Gender-based subgroup analysis with men                                  1.21   0.89,1.63      65       0.23
  Gender-based subgroup analysis with women                                1.15   0.97,1.35      39        0.1
  Recessive model (Glu/Glu vs. Gln/Gln + Gln/Glu)                          0.99   0.80,1.22      39       0.93
  Gender-based subgroup analysis with men                                  0.92   0.66,1.30       0       0.65
  Gender-based subgroup analysis with women                                1.28   0.72,2.27      64       0.39

Abbreviations: OR, odds ratio; CI, confidence interval; *I* ^2^, Cochran\'s c--based Q-statistic test for assessing the heterogeneity (\>50% indicates a substantial heterogeneity).

10.1371/journal.pone.0100489.t005

###### Meta-analysis of rs1042713 (Arg16Gly) polymorphisms on risk of obesity.
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  Comparisons rs1042713 (Arg16Gly) polymorphism and obesity (10studies)     OR      95%CI     *I^2^*(%)   *P*
  ----------------------------------------------------------------------- ------ ----------- ----------- ------
  Allele frequency comparison (Arg vs. Gly)                                1.02   0.95,1.10      25       0.52
  Gender-based subgroup analysis with men                                  0.89   0.74,1.08      51       0.24
  Gender-based subgroup analysis with women                                1.1    0.99,1.23      27       0.08
  Heterozygote comparison (Arg/Gly vs. Arg/Arg)                            1.05   0.93,1.19       9       0.39
  Gender-based subgroup analysis with men                                  1.1    0.91,1.31      27       0.32
  Gender-based subgroup analysis with women                                0.99   0.82,1.20       0       0.92
  Homozygote comparison (Gly/Gly vs. Arg/Arg)                              0.95   0.82,1.09      24       0.47
  Gender-based subgroup analysis with men                                  1.1    0.90,1.36      44       0.34
  Gender-based subgroup analysis with women                                0.71   0.47,1.07      53       0.1
  Dominant model (Arg/Gly + Gly/Gly vs. Arg/Arg)                           1.02   0.91,1.14      15       0.74
  Gender-based subgroup analysis with men                                  1.1    0.93,1.30      46       0.26
  Gender-based subgroup analysis with women                                0.92   0.77,1.11       0       0.39
  Recessive model (Gly/Gly vs. Arg/Arg + Arg/Gly)                          0.92   0.82,1.04       8       0.17
  Gender-based subgroup analysis with men                                  1.04   0.88,1.23       0       0.61
  Gender-based subgroup analysis with women                                0.67   0.44,1.02      71       0.06

Abbreviations: OR, odds ratio; CI, confidence interval; *I* ^2^, Cochran\'s c--based Q-statistic test for assessing the heterogeneity (\>50%indicates a substantial heterogeneity).

Evaluation of publication bias {#s3c}
------------------------------

Publication bias was assessed by the funnel plot and Egger\'s test. The funnel plot (heterozygote Gln/Glu vs. Gln/Gln) showed no apparent evidence of publication bias ([Fig. 4](#pone-0100489-g004){ref-type="fig"}). There was also no significant difference in Egger\'s test for the allelic genetic model, which suggested that the probability of publication bias was low in the present meta-analysis (t = 0.84, P = 0.424).

![Funnel plot for rs1042714 (Gln27Glu) gene polymorphism on heterozygote Gln/Glu vs.\
Gln/Gln. The funnel plot showed no apparent evidence of publication bias.](pone.0100489.g004){#pone-0100489-g004}

Subgroup analyses by gender in the current study {#s3d}
------------------------------------------------

Taking into account possible gender-specific roles in etiology [@pone.0100489-Chou1], we conducted subgroup analyses by gender in the present study. After stratification for gender, no significant correlation of the rs1042714 (Gln27Glu) or rs1042713 (Arg16Gly) polymorphisms to obesity was observed in any of the genetic models ([Table 4](#pone-0100489-t004){ref-type="table"} and [Table 5](#pone-0100489-t005){ref-type="table"}, respectively).

Discussion {#s4}
==========

Several studies involved in ADRB2 polymorphisms and obesity have been published [@pone.0100489-Pereira1], [@pone.0100489-Lee1], [@pone.0100489-Large1], [@pone.0100489-Caramelli1]. However, published results are controversial. For example, Pereira et al. reported that Arg16Gly (rs1042713) was not a major contributing factor for obesity in Japanese men; however, it is believedto have a significant association with obesity in Japanese women [@pone.0100489-Pereira1]. Large et al. [@pone.0100489-Large1] reported thatADRB2 gene polymorphisms were markedly associated with obese Caucasian women. However, Echwald [@pone.0100489-Echwald1] and Oberkofler [@pone.0100489-Oberkofler1] found no association between ARDB2 and obesity. Specifically, a study performed by Oberkofler [@pone.0100489-Oberkofler1] concluded that the two polymorphisms of Gln27Glu (rs1042714) and the Arg16Gly (rs1042713) in the ARDB2 gene are not a major factor contributing to obesity in Austrian women. Moreover, Echwald et al. found the Glu27 polymorphism of ARDB2 gene is not associated with obesity in the population of Danish Caucasian men. However, Ehrenborg [@pone.0100489-Ehrenborg1] found that individuals carrying the E27 allele and/or the G16 allele had significantly higher BMI, and that the E27 allele of the beta2-adrenoceptor gene is associated with slightly to moderately elevated BMI.

In 2007, Gjesting and colleagues [@pone.0100489-Gjesing1] conducted a case-control study and meta-analysis examining 7,808 white people for eirany association between ADRB2 polymorphisms and obesity. In their study, genotype distribution of ADRB2 Gln27Glu and Arg16Gly was provided according to diabetic people and non-diabetic subjects. However the data of ADRB2 data according to obesity and controls were not available. Hence the article was excluded from our present meta-analysis. Their analysis provided the data of BMI stratified according to ADRB2 Gln27Glu and Arg16Gly genotype and they did not find significant correlation between these beta2-adrenergic receptor variants (both)and obesity. Furthermore, they did not find that the quantitative trait analyses showed any effect of the variants on obesity-related traits.

In 2008, Jalba and colleagues [@pone.0100489-Jalba1] performed a meta-analysis involving ADRB2 gene and obesity and conducted statistical analysis in three ways: the heterozygote comparison (Gln/Glu vs. Gln/Gln), the homozygote comparison (Glu/Glu vs. Gln/Gln) and the dominant model (Gln/Glu + Glu/Glu vs. Gln/Gln). Their results suggested that rs1042714 might be a significant risk factor for obesity in Asians, Pacific Islanders, and American Indians, but not in Europeans. Also, the report showed that obesity might not be associated with rs1042713 at all.

Since the association of ADRB2 polymorphisms with obesity is controversial, we conducted this meta-analysis based on all current available data on the relation between ADRB 2 polymorphism and obesity in 18 publications in order to clarify their relationship. Our findings suggest that there is a significant association between rs1042714 polymorphism of ADRB2 and obesity: OR = 0.86 for the allelic genetic model, OR = 1.2 for the dominant genetic model, OR = 0.99 for the recessive genetic model, OR = 1.01 for the homozygote genetic model, OR = 1.16 for the heterozygote genetic model.

In dominant comparison, the risk of developing obesity with Gln/Glu plus Glu/Glu genotype was 1.2 times higher than those with Gln/Gln homozygotes. However, our meta-analysis suggested no significant correlation of the rs1042714 (Gln27Glu) polymorphism to obesity in the other three comparisons. Also, no significant correlation to obesity was found for the rs1042713 polymorphism in all genetic models in the total population, as well as in gender-specific populations. This may be due to the divergence in genetic background. For example, the strength of the association between either rs1042713 or rs1042714 and obesity may be variable in different populations. Compared with the study of Jalba et al [@pone.0100489-Jalba1], we not only performed the following comparisons such as the heterozygote comparison (Gln/Glu vs. Gln/Gln), homozygote comparison (Glu/Glu vs. Gln/Gln) and dominant model (Gln/Glu + Glu/Glu vs. Gln/Gln), but we also conducted comparisons such as frequency of allele (Gln vs. Glu) and recessive model (Glu/Glu vs. Gln/Gln + Gln/Glu). In addition, we performed subgroup analyses by gender in the present study. Therefore, our results have stronger statistical power. Our meta-analysis suggest that Gln27Glu polymorphism of ADRB2 in heterozygote model showed a greater significance (p = 0.009) when compared to dominant model (p = 0.04). It may be a possible reflection of the linkage disequilibrium of genetic variability in codons 27 and gene-environment interaction in the etiology of obesity, since the mechanism of how Glu 27 can promote obesity is unknown at present. The results of our current meta-analysis support the conclusion that obesity susceptibility is associated with the Gln27Glu polymorphism of ADRB2 rather than the Arg16Gly polymorphism. This is different from previous results by Echwald [@pone.0100489-Echwald1] and Oberkofler [@pone.0100489-Oberkofler1] et al. Furthermore, our findings are inconsistent with the results of Gjesting [@pone.0100489-Gjesing1]. No association of ADRB2 (both) with obesity risk was observed in our meta-analysis upon gender stratification. However, our results support the conclusion from Jalba [@pone.0100489-Jalba1].

Though our study provides the most comprehensive and up-to-date meta-analysis regarding the association between ADRB2 polymorphism with obesity, but also evaluates the methodological quality of 18 studies including our meta-analysis. Our work has some limitations. First, obesity is a complicated status involving complex interactions of genes, environment, and other factors, such as diet, lifestyle, diabetes mellitus, hypertension, total cholesterol, triglycerides, HDL and LDL. Though majority of publications included in our meta-analysis considered the factors described above such as diabetic factor, several articles did not consider the factors. See [table 2](#pone-0100489-t002){ref-type="table"}. However, other susceptible factors were not able to be analyzed in the current study because insufficient data were provided from some of the original studies. Hence, misclassification bias is still possible. Moreover, only two studies [@pone.0100489-Pereira1], [@pone.0100489-Angeli1] explicitly stated that they have no conflict of interest, the others did not state whether they have conflict of interest or not. Therefore, possible conflicts of interests in studies enrolled in our meta-analyses may result in a bias.

Second, different BMI values were used as a cut-off in enrolling studies. Asian populations require a lower BMI to indicate that an individual is at the same risk as a European, and this variation can be explained by WHO expert consultations [@pone.0100489-Consultation1]. Out of our included studies, BMI of less than 30 was used in four out of five Asian studies at codon 27 and all seven Asian studies at codon 16. The specific details of variations in BMI cut point are shown in [Table 1](#pone-0100489-t001){ref-type="table"}. It is not feasible to have the same BMI cut-off as obesity criteria across population from different geographical locations.

Third, our results were based on an unadjusted estimate, a more precise analysis should be performed adjusted by age, smoking, and other factors. Lack of the original data of the enrolled publications limit our further evaluation of potential interactions such as gene-gene, gene-environmental factors, which may affect obesity risk.

Lastly, although our funnel plot and Egger\'s test results showed no evidence of sample selection bias, it is still a remote possibility that such selection bias may have inadvertently occurred, and future meta-analysis studies may wish to recheck these conclusions as new research data continues to be published.

In summary, our results clarify that the overall conclusion of the literature to date indicates a significant association of Gln27Glu polymorphism with increased risk of obesity. Interestingly, increased risk of obesity is associated only with the Gln27Glu polymorphism of ADRB2, not the Arg16Gly polymorphism. This result sets the stage for future biochemical studies to investigate the mechanisms underlying this polymorphism-specific risk factor. Our conclusion also provides a basis to recognize patients at higher risk for obesity, allowing clinicians to more accurately create strategies for individualized therapy in obese patients.
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